2007 ASCO Annual Meeting - Phase I/II-data On Systemic Application Of The TGF-beta2-inhibitor AP 12009 To Be Presented

Main Category: Cancer / Oncology
Also Included In: Melanoma / Skin Cancer
Article Date: 12 May 2007 - 12:00 PDT

email to a friend   printer friendly   opinions  

Antisense Pharma today announced, that the abstract entitled Preliminary Results of a Phase I/II-Study in Pancreatic Carcinoma, Malignant Melanoma, and Colorectal Carcinoma with the TGF-beta2 Inhibitor AP 12009 has been selected for poster presentation at the 43rd Annual Meeting of the American Society of Clinical Oncology (ASCO), which will be held in Chicago, Illinois, U.S.A, from June 1st - 5th. In the Phase I/II-trial the antisense drug AP 12009 is administered intravenously in patients with either pancreatic carcinoma (stage IVA/IVB), metastatic melanoma (stage III/IV), or advanced colorectal carcinoma (stage III/IV) as a 7-day continuous infusion every other week.

"The first milestone of the study has been achieved, as the maximum tolerated dose was determined with this treatment schedule", explains Hubert Heinrichs, M.D., Ph.D., Chief Medical Officer at Antisense Pharma. Patient recruitment is still ongoing in study sites in Germany as further dose escalations with a modified dosing schedule are now performed. The design of the study, first efficacy and safety data will be presented at the poster presentation (Poster Board No. AA5, Abstract ID 4607) on June 4th 2007 from 8:00 a.m. to 12:00 p.m. in the session Gastrointestinal (Noncolorectal) Cancer. Prof. Thomas Seufferlein, Vice Head of the Department of Internal Medicine at the University of Ulm and Principal Investigator of the Phase I/II-Study will be available for questions from 11:00 a.m. to 12:00 p.m. at the poster in Hall A2 on Level 3 of McCormick Place South Building.

About Antisense Pharma

Antisense Pharma is a biopharmaceutical company located in Regensburg, Germany. The company focuses on targeted therapies for malignant tumors and is dedicated to discovering and developing drugs based on antisense technology for worldwide commercialization. The agents specifically block the synthesis of key cancer proteins. The lead product - AP 12009 - a Transforming Growth Factor-beta2 inhibitor - is in advanced clinical development for the treatment of high-grade glioma as well as in Phase I/II clinical trial for the treatment of colorectal carcinoma, pancreatic carcinoma, and malignant melanoma. The further product pipeline covers preclinical drug candidates as well as compounds in research and discovery. Antisense Pharma has been honored with the Bavarian Innovation Award and the German Founders Award.

http://www.antisense-pharma.com

• Additional
• References
• Citations